Poxel S.A. (PXXLF)

Overview

Poxel S.A. is a pivotal player in the biopharmaceutical landscape, focusing its efforts on the discovery and development of innovative treatments for a range of metabolic diseases, including type 2 diabetes and various liver conditions. With its inception in 2009, the company has positioned itself at the forefront of addressing mitochondrial dysfunction, seeking to offer novel therapeutic options for chronic and increasingly prevalent diseases. Headquartered in Lyon, France, Poxel S.A. demonstrates its commitment to advancing healthcare and improving patient outcomes through a robust pipeline of drug candidates, strategic partnerships, and a focus on unmet medical needs in the metabolic disease space.

Products and Services

Under the purview of Poxel S.A.’s innovative research and development, several key products and drug candidates are spearheading the company’s mission to combat metabolic diseases:

• TWYMEEG (Imeglimin): This oral drug candidate stands out as Poxel S.A.’s lead product, approved in Japan for the treatment of type 2 diabetes. By targeting mitochondrial dysfunction, Imeglimin represents a novel approach in diabetes care, addressing a fundamental aspect of the disease’s pathology.
• PXL770: Positioned in the company’s pipeline is PXL770, a potent adenosine monophosphate-activated protein kinase (AMPK) enzyme activator. Currently in a Phase 2a clinical trial, PXL770 is explored for its potential in treating chronic metabolic diseases, prominently including non-alcoholic steatohepatitis (NASH), a severe liver disease with limited treatment options.
• PXL065: Another significant addition to Poxel’s portfolio, PXL065 is under investigation in a Phase 2 clinical trial for the treatment of NASH. It is notable for its focus on chronic and rare metabolic conditions, representing a differentiated approach through the inhibition of the mitochondrial pyruvate carrier, a novel target in the treatment of metabolic diseases.

In addition to these proprietary developments, Poxel S.A. engages in strategic collaborations to broaden its research and therapeutic horizons:

• Enyo Pharma S.A.S. Agreement: This licensing agreement facilitates the joint development of a farnesoid X receptor, presently in a Phase 2a study. This collaborative effort focuses on addressing hepatitis B and NASH, leveraging shared expertise to tackle these challenging liver diseases.
• DeuteRx LLC Partnership: A collaboration that underscores Poxel’s commitment to innovation, working with DeuteRx LLC on developing PXL065 for NASH treatment. This partnership aims to harness complementary strengths, potentially accelerating the path to delivering a new therapeutic option for NASH patients.